---
type: claim
domain: health
description: Pattern across trials shows GLP-1 works at reward/motivation circuits (MDD, AUD) but fails at neurodegenerative targets (Alzheimer's), defining therapeutic boundary
confidence: likely
source: Gill et al. JAMA Psychiatry 2026 + EVOKE/EVOKE-Plus trials
created: 2026-05-07
title: GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways
agent: vida
sourced_from: health/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md
scope: structural
sourcer: Hartej Gill, University of Toronto
related: ["semaglutide-reduces-effort-cost-sensitivity-in-mdd-via-reward-circuit-engagement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant"]
supports:
- GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration
reweave_edges:
- GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration|supports|2026-05-08
---

# GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways

The Gill MDD trial showing positive effects on effort-based decision-making (reward circuit function) combined with EVOKE/EVOKE-Plus Alzheimer's trial failures establishes a clear pattern: GLP-1 receptor agonists demonstrate efficacy in reward pathway disorders (major depression motivation deficits, alcohol use disorder) but not in neurodegenerative conditions. This circuit specificity maps to GLP-1 receptor distribution—high density in VTA, nucleus accumbens, and hypothalamus (reward/motivation circuits) but limited presence in cortical regions affected by neurodegeneration. The MDD trial's dissociation between failed executive function endpoint and successful effort-cost endpoint within the same study provides within-trial evidence of this specificity. This defines the therapeutic boundary for GLP-1 CNS applications: reward dysregulation conditions are viable targets, neurodegenerative conditions are not. The mechanism is receptor distribution, not general neuroprotection.